2023-05-04 06:32:01 ET
- Regeneron Pharmaceuticals press release ( NASDAQ: REGN ): Q1 Non-GAAP EPS of $10.09 beats by $0.53 .
- Revenue of $3.16B (+6.4% Y/Y) beats by $160M .
- First quarter 2023 Dupixent ® global net sales (recorded by Sanofi) increased 37% to $2.49 billion versus first quarter 2022
- First quarter 2023 EYLEA ® U.S. net sales were $1.43 billion
- First quarter 2023 GAAP diluted EPS of $7.17 and non-GAAP diluted EPS (a) of $10.09; includes unfavo rable $0.42 impact from acquired IPR&D charge
For further details see:
Regeneron Pharmaceuticals Non-GAAP EPS of $10.09 beats by $0.53, revenue of $3.16B beats by $160M